• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Alcon

Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?

By Pallavi Madhiraju on April 8, 2026   Pharma & Biotech  

Can Alcon turn baseball fandom into a growth engine for Systane in Canada’s dry eye category?

See how Alcon is using the Toronto Blue Jays to expand Systane’s dry eye reach in Canada and what it means for eye care competition.

Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?

By Pallavi Madhiraju on April 7, 2026   Medical Devices & Diagnostics  

Is Alcon redefining the enhanced monofocal category with Clareon TruPlus at ASCRS 2026?

Alcon launched Clareon TruPlus at ASCRS 2026. Read why the new enhanced monofocal IOL could reshape cataract lens choice.

Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care

By Pallavi Madhiraju on February 19, 2026   Medical Devices & Diagnostics  

Why Alcon’s TOTAL30 Multifocal for Astigmatism targets the toughest segment in contact lens care

Alcon has launched TOTAL30 Multifocal for Astigmatism in the U.S. Find out why this matters for presbyopia care and contact lens adoption.

Recent Posts

  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
  • Why Aphranel’s EU MDR approval could sharpen competition in CaHA dermal fillers
  • Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
  • Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
  • Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
  • Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes